NASDAQ:BTAI BioXcel Therapeutics Q4 2024 Earnings Report $1.19 +0.06 (+5.31%) Closing price 04:00 PM EasternExtended Trading$1.20 +0.01 (+0.42%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast BioXcel Therapeutics EPS ResultsActual EPS-$3.57Consensus EPS -$4.36Beat/MissBeat by +$0.79One Year Ago EPSN/ABioXcel Therapeutics Revenue ResultsActual Revenue$0.30 millionExpected Revenue$0.72 millionBeat/MissMissed by -$420.00 thousandYoY Revenue GrowthN/ABioXcel Therapeutics Announcement DetailsQuarterQ4 2024Date3/27/2025TimeBefore Market OpensConference Call DateThursday, March 27, 2025Conference Call Time10:30AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) BioXcel Therapeutics Earnings HeadlinesBioXcel Therapeutics (BTAI) Projected to Post Quarterly Earnings on TuesdayAugust 10, 2026 | americanbankingnews.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Average Rating of "Hold" by AnalystsAugust 3, 2026 | americanbankingnews.comAI insiders stockpile guns, gold & gas masksKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift in the AI market is approaching, and time is short to prepare. Kaplan points to August 31st as a key turning point for AI investing. He argues the next phase will separate winners from losers, and reveals what he's watching instead of big names like Nvidia.August 14 at 1:00 AM | TradeSmith (Ad)BioXcel Therapeutics Amends Credit Agreement, Tightens LiquidityJuly 27, 2026 | theglobeandmail.comBioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual MeetingMay 28, 2026 | globenewswire.comBioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comSee More BioXcel Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioXcel Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioXcel Therapeutics and other key companies, straight to your email. Email Address About BioXcel TherapeuticsBioXcel Therapeutics (NASDAQ:BTAI) is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes. BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option. ZYESAMI® (aviptadil) is authorized for the treatment of acute respiratory distress syndrome, including in patients with critical COVID-19–related respiratory failure, representing the company’s expansion into critical care medicine. In addition to its marketed products, BioXcel maintains a diversified pipeline of clinical and preclinical programs targeting neuropsychiatric and immuno-oncology indications. The company collaborates with academic institutions and strategic partners to further validate its AI-identified assets and explore new indications, underpinning its strategy to deliver differentiated treatments across multiple therapeutic areas. Founded in 2017 and headquartered in New Haven, Connecticut, BioXcel Therapeutics completed its public listing in 2019. The company currently serves the U.S. market and is evaluating opportunities for global expansion. Under the leadership of President and CEO Vimal Mehta, M.D., Ph.D., BioXcel is focused on growing its commercial footprint and advancing its AI-enabled pipeline toward key regulatory milestones.View BioXcel Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
